A novel clinical study has found that nutraceutical powerhouse Kerry Group's Sensoril ashwagandha can support women's health post-menopause.
The findings, which were published in the Journal of Menopausal Medicine, highlight the Ayurvedic ingredient's ability to reduce unpleasant symptoms associated with the menopause, as well as supporting sexual health and energy levels.
This is the 15th study to be conducted on Sensoril — with previous studies highlighting its potential in the beauty from within, healthy ageing, sleep, stress support and active nutrition spaces.
Ashwagandha has been in the news recently due to its ban in Denmark, though it still remains popular as a herbal health-booster in many countries, including Canada.
To find out more about the study, the potential of ashwagandha use for women keen to avoid hormone replacement therapy (HRT) and the science behind Sensoril's efficacy, NBR caught up with Dr Monica Maria Olivares, RDA Director of Women’s & Infant Health at Kerry.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.